OncoMatch/Clinical Trials/NCT07722494
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
Is NCT07722494 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including IBI363 + bevacizumab and Investigator's choice of therapy for colorectal cancer.
Treatment: IBI363 + bevacizumab · Investigator's choice of therapy — This is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Required: Mismatch-repair proficient (pMMR / MSS)
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG PS score of 0 or 1
Prior therapy
Must have received: systemic therapy for metastatic colorectal cancer — metastatic disease
Has experienced treatment failure or intolerance to prior systemic standard therapies administered for metastatic disease, with failure or intolerance occurring on the most recent line of systemic therapy
Cannot have received: fruquintinib, trifluridine/tipiracil (TAS-102), and regorafenib (fruquintinib, trifluridine/tipiracil, TAS-102, regorafenib)
Prior disease progression, treatment intolerance, or contraindication to all three agents: fruquintinib, trifluridine/tipiracil (TAS-102), and regorafenib
Cannot have received: anti-PD-(L)1 or PD-L2 immunotherapy in the metastatic setting
Prior receipt of immunotherapy targeting anti-PD-(L)-1 or PD-L2 in the metastatic setting
Cannot have received: anti-PD-(L)1 immunotherapy or anti-VEGF therapy
Exception: unless not associated with severe toxicities requiring permanent discontinuation or contraindication
History of severe toxicities related to anti-PD-(L)-1 immunotherapy or anti-VEGF therapy that necessitated permanent discontinuation of treatment, or contraindication to any of the above agents
Cannot have received: interleukin (IL)-2 or IL-15 cytokines (IL-2, IL-15)
Prior administration of interleukin (IL)-2 or IL-15 cytokines
Lab requirements
Blood counts
Kidney function
Liver function
Confirmed adequate bone marrow and organ function at screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07722494 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior fruquintinib, trifluridine/tipiracil (TAS-102), and regorafenib, anti-PD-(L)1 or PD-L2 immunotherapy in the metastatic setting, anti-PD-(L)1 immunotherapy or anti-VEGF therapy disqualifies patients from enrollment.
Does this trial require MLH1?
Yes, MLH1 wild-type is a required biomarker for enrollment.
Does this trial require MSH2?
Yes, MSH2 wild-type is a required biomarker for enrollment.
Does this trial require MSH6?
Yes, MSH6 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages